

## PERSONAL INFORMATION

Gualberto Gussoni



Sex M | Date of birth | Nationality

JOB APPLIED FOR  
POSITION  
PREFERRED JOB  
STUDIES APPLIED FOR  
PERSONAL STATEMENT

## WORK EXPERIENCE



From 2023 to today **President**  
RIDE2Med Foundation, Milan, Italy

From 2007 to 2023 **Scientific Director**  
"Centro Studi" FADOI / Fondazione FADOI – Italian Scientific Society of Internal Medicine, Milan, Italy

From 2016 to 2017 **Head of Clinical Trials Office**  
University Campus Bio-Medico, Rome, Italy

From 1999 to 2006 **Head of Cardiovascular and Internal Medicine Projects**  
Medical Department, Italfarmaco S.p.A, Milan, Italy

From 1998 to 1999 **Clinical Project Leader**  
Medical Department, Recordati S.p.A, Milan, Italy

From 1994 to 1998 **Medical Project Leader – Head of Pharmacovigilance**  
Medical Department, Beaufour-Ipsen Group, Milan, Italy

From 1993 to 1994 **Clinical Monitor - Project Leader**  
Medical Department, Italfarmaco S.p.A., Milan, Italy

From 1992 to 1993 **Clinical Monitor – Clinical Research Associate**  
Medical Department, Crinos S.p.A., Villaguardia (CO), Italy

From 1991 to 1991 **General Practitioner**  
Varese, Italy

---

**EDUCATION AND TRAINING**

---

From 1993 to 1995 **Specialization in Pharmacology**  
University of Milan, Italy

From 1983 to 1990 **Degree in Medicine and Surgery**  
University of Pavia, Italy

From 1988 to 1991 **Traineeship in Medicine and Surgery**  
Clinica Medica, University of Pavia, Hospital of Varese, Italy

From 1992 to today **Attendance to more than 150 Medical Congresses**  
Italy, European Countries, North and South America, China

---

**PERSONAL SKILLS**

---

Mother tongue(s) Italian

Other language(s)	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	B1	B2	B2	B2	B2
French	A1	A2	A1	A1	A1

**Communication skills** Good communication skills gained through the experience of coordinator of working groups and public speaker in national and international scientific congresses and meetings

**Organisational / managerial skills** Good organisational and managerial skills gained through the activity of project management of research and educational projects and hierarchical responsibility of professional teams (from 2 to 10 people) or functional responsibility (up to 100 people)

#### Job-related skills

Digital skills	SELF-ASSESSMENT				
	Information processing	Communication	Content creation	Safety	Problem solving
	Basic user	Basic user	Basic user	Basic user	Basic user

#### Other skills

**Driving licence** Driving licence B

#### ADDITIONAL INFORMATION

**Publications**

- Author of more than 90 full scientific articles in national and international journals (see Annex 1) – H-Index 19, and a number of abstracts (more than 100) for national and international congresses.
- Author of a number of informative articles in journals in the medical-scientific field
- Official Reviewer Journal of Thrombosis and Haemostasis
- Reviewer Thrombosis and Haemostasis
- Reviewer Postgraduate Medicine
- Member of the Editorial Board Italian Journal of Medicine
- Member of the Editorial Board PharmAdvances
- Guest Editor of Supplements Italian Journal of Medicine
- Editor of the White Papers "La Ricerca Clinica come investimento per l'Italia: dalle parole all'azione. Una proposta in 10 punti. Documento sulla Ricerca Clinica da Promotori no profit" (2016) / "Dentro la Ricerca: la Persona prima di tutto. Una proposta in 10 punti. Documento sulla ricerca clinica da Promotori no profit" (2018) / "Il valore della ricerca clinica indipendente in Italia – Libro Bianco sulla ricerca clinica in Italia: dalle fonti di finanziamento al valore etico e sociale" (2019) / "Terapie digitali, un'opportunità per l'Italia" (2021) / "Digital therapeutics an opportunity for Italy, and beyond" (2021) / "La ricerca biomedical e il rapporto pubblico-privato" (2021) / "Implementazione degli Studi Clinici Decentralizzati in Italia: perché e come? Multi-stakeholder expert opinion su aspetti metodologici, regolatori, etici e formativi" (2022) / "Implementing Decentralized Clinical Trials in Italy: why and how? Multi-stakeholder expert opinion on priorities for methodology, regulatory affairs, ethics and training" (2022)
- Co-author of the following Reports of the Italian Istituto Superiore di Sanita' for the CoViD-19 pandemic "Research ethics during the COVID-19 pandemic: observational and, in particular, epidemiological studies" (2020) / "Digital support for contact tracing during the pandemic ethical and

governance considerations" (2020) / "Comunicazione in emergenza nei reparti COVID-19. Aspetti di etica" (2020) / "Il Medico di Medicina Generale e la pandemia di COVID-19. Alcuni aspetti di etica e di organizzazione" (2020) / "Ethical aspects in the testing of anti-COVID-19 vaccines" (2021)

<b>Projects</b>	Planning and/or coordination of around 90 projects of clinical and preclinical research Coordinator of the Project "Terapie Digitali, un p'opportunita' per l'Italia – #DTxITA" promoted by Fondazione Smith Kline (2019-2021) Coordinator of the Project "Decentralized Clinical Trial per l'Italia – DCTxITA" promoted by Fondazione Smith Kline (2021-2022) Director of a Second Level Post-Graduate Master for Clinical Research, University UnitelmaSapienza, Rome (2022-2023)
<b>Conferences</b>	- Founder and coordinator of the Italian National Congress on not-for-profit Research (6 Editions) and related position Documents - Coordinator of Courses for methodology of clinical research for young Internists and Nurses - Speaker and/or Chairman in more than 150 national and international Congresses
<b>Seminars</b>	- Invited Speaker for Seminars at Italian Universities (Milan – Padua – Bologna – Siena – Pisa – Florence – Genova – Naples – Rome - Catania) - Teacher at Libera Università Carlo Cattaneo (LIUC), Castellanza - Teacher at Libera Università Internazionale degli Studi Sociali Guido Carli (LUISS), Rome - Teacher at University Sapienza, Rome - Teacher at University Campus Biomedico, Rome - Teacher Contract years 2003-2004 – University of Pavia - Member of the Scientific Board and Teacher Master of Second Level "Farmacovigilanza, Farmacoepidemiologia e attività regolatorie" – University "Luigi Vanvitelli", Naples
<b>Honours and awards</b>	Awards for Best Clinical Research at the following Congresses - Congress "Somatostatin analogues: basic update and clinical perspectives" – Venice, 1997 - Congress of the American Society of Hematology – San Diego, 2008 - World Congress of Internal Medicine, Santiago (Chile), 2012 - Congress of the European Federation of Internal Medicine, Geneve, 2014 Honorary Fellow of the Italian Scientific Society of Internal Medicine FADoI Honorary Fellow of the Italian Association of Data Managers (GIDM)
<b>Memberships</b>	- Italian Scientific Society of Internal Medicine (FADoI) - Italian Association of Data Managers (GIDM) - Italian Society of Pharmacology (SIF), acting as Board Member of the Clinical Pharmacology Chapter of the Society (2015-2019) - Italian Society of Pharmaceutical Medicine (SIMeF) - Association of Pharmaceutical Professionals of the Industry (AFI) - Member of the Working Group "Bioetica – Covid-19" of the Italian Istituto Superiore di Sanità - Member of the Healthcare Professional Working Party at European Medicines Agency as Representative of the European Federation of Internal Medicine (2019-2022 and 2022-2025 mandate), until December 31, 2023 - Individual Expert, European Medicines Agency (starting from January 2024) - Member of the Technical-Scientific Committee of the Intergruppo Parlamentare per la Sanità digitale e le Terapie Digitali" of the Italian Parlament (starting from 2023)
<b>References</b>	
<b>Citations</b>	
<b>Courses</b>	
<b>Certifications</b>	
<b>ANNEXES</b>	Annex 1 – List of published full papers

I authorize the processing of personal data included in the present curriculum vitae according to Decreto Legislativo 30 giugno 2003, n.196 "Codice in materia di protezione dei dati personali" and the subsequent national and international rules in force, including the European Regulation 2016/679 and the Italian Decreto Legislativo 101/2018.

March 6, 2024

Signature

Pursuant to and for the purposes of articles 46 and 47 of DPR 28.12.2000 n.445, aware of the criminal sanctions referred to in Article 76 of the same, in the event of false declarations or use of false documents, I declare that I have the qualifications indicated in this curriculum vitae et studiorum, reserving the right to produce, upon request, qualifications and certificates useful for evaluating my position that are not already in my personal file.

March 6, 2024

Signature

#### ANNEX 1 - LIST OF PUBLISHED FULL PAPERS

- 1) "Febbricola e splenomegalia di difficile inquadramento"  
Bollettino dell'Ospedale di Varese 1990; 19: 251-3
- 2) "La terapia anticoagulante orale: indicazioni e ranges terapeutici"  
Bollettino dell'Ospedale di Varese 1991; 20: 641-7
- 3) "La piastrinopenia HIV-correlata"  
Bollettino dell'Ospedale di Varese 1991; 20: 756-765

- 4) "La Zidovudina nel trattamento della piastrinopenia HIV-correlata: uno studio di 11 casi"  
Recenti Progressi in Medicina 1991; 82: 397-9
- 5) "Osservazioni su un caso di amiloidosi primaria"  
Giornale di Clinica Medica 1991; 72: 511-14
- 6) "Defibrotide versus pentoxifylline in patients with peripheral occlusive arterial disease"  
Acta Therapeutica 1994; 19: 181-90
- 7) "Defibrotide versus placebo in the treatment of intermittent claudication: a meta-analysis"  
Drug Investigation 1994; 7: 157-60
- 8) "Effectiveness and tolerability of slow-release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study"  
Journal of Clinical Endocrinology & Metabolism 1996; 81 : 2089-97
- 9) "Effects of long-term slow-release lanreotide treatment in selected patients with active acromegaly"  
in "Pituitary Adenomas: From Basic Research to Diagnosis and Therapy", K.von Werder, R.Fahlbusch eds. Elsevier Science, 55-59: 1996
- 10) "A somatostatin analogue inhibits MAP kinase activation and cell proliferation in human neuroblastoma and in human small cell lung carcinoma cell lines"  
FEBS Letter 1996; 397: 164-8
- 11) "Effectiveness and tolerability of slow-release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study - Authors' response"  
Journal of Clinical Endocrinology & Metabolism 1996; 81: 4502-3
- 12) "Clinical results of long-term slow-release lanreotide treatment of acromegaly"  
European Journal of Clinical Investigation 1997; 27: 277-284
- 13) "Long-term results with the slow-release formulation of lanreotide in acromegalic patients"  
Journal of Endocrinological Investigation 1997; 20 (suppl. to n.7): 37-42
- 14) "Uneventful pregnancy in one acromegalic patient treated with slow-release lanreotide, a case report"  
Journal of Clinical Endocrinology and Metabolism 1999; 84(4): 1489
- 15) "Somatostatin and its analogue lanreotide inhibit the proliferation of dispersed human non- functioning pituitary adenoma cells in vitro"  
European Journal of Endocrinology 1999; 141: 396-408
- 16) "Tromboembolismo arterioso acuto periferico: trattamenti complementari"  
In "Le emergenze vascolari", C.Pratesi, R. Pulli eds, Minerva Medica, 2004
- 17) "Is it possible to improve outcome in patients undergoing surgery for acute limb ischemia? Can iloprost, a prostacyclin analogue, be helpful?"  
Chirurgia Italiana 2004; 56: 769-80
- 18) "Central venous catheters in haematological patients: a prospective multicenter study on thrombotic complications"  
Br J Haematol 2005; 129: 811-7
- 19) "A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project"  
Ann Surg 2006; 243: 89-95
- 20) "Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impairment of glucose metabolism"  
Nutr Metab Cardiovasc Dis 2006; 16: 137-47
- 21) "The ILAAILL Study: Iloprost as adjuvant to surgery for acute ischemia of lower limbs. A randomized, double-blind, placebo-controlled study by the Italian Society for Vascular and Endovascular Surgery"

Ann Surg 2006; 244: 185-93

22) "Clinically overt venous thromboembolism after urologic cancer surgery: results from the @RISTOS study"  
Eur Urol 2007; 51: 130-5

23) "Acute limb ischemia in elderly patients: can iloprost be useful as adjuvant to surgery? Results from the ILAILL study"  
Eur J Vasc Endovasc Surg 2007; 34: 194-198

24) "Linee-guida e gestione ospedaliera delle polmoniti acquisite in comunità: l'esperienza italiano dello studio FASTCAP"  
Italian Journal of Medicine 2008; 2: 5-18

25) "Studio FASTCAP – gestione ospedaliera delle polmoniti acquisite in comunità: valutazione farmacoeconomica della fase prospettica"  
Italian Journal of Medicine 2008; 2: 55-66

26) "The potential role of iloprost as adjuvant to surgery for acute limb ischemia: findings from the ILAILL study"  
Vasc Dis Manag 2008; 5: 155-161

27) "Clinical governance: the viewpoint of the clinician"  
Il Patologo Clinico – Journal of Molecular and Clinical Pathology 2009

28) "In-hospital symptomatic venous thromboembolism and antithrombotic prophylaxis in Internal Medicine: findings from a multicenter, prospective study"  
Thrombosis and Haemostasis 2009; 101: 893-901

29) "Farmaci per il trattamento iniziale del tromboembolismo venoso: eparina non frazionata, eparine a basso peso molecolare, fondaparinux, trombolitici, nuovi anticoagulanti"  
Italian Journal of Medicine 2009; 3 (1 Suppl.2): 3-10

30) "Le polmoniti nei pazienti provenienti da Residenze Sanitarie Assistenziali: è necessaria una strategia terapeutica dedicata?"  
Italian Journal of Medicine 2009; 3(4): 212-9

31) "Medicina Interna, paziente complesso, evidence based medicine e le non evidenze"  
Italian Journal of Medicine 2009; 3(4): 191-200

32) "Fattori di rischio per tromboembolismo venoso e profilassi nei pazienti ricoverati in Medicina Interna: analisi dallo studio FADOI "GEMINI""  
Italian Journal of Medicine 2010; 4(1): 24-31

33) "Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study"  
Lancet Oncology 2009; 10: 943-9

34) "Prevention of venous thromboembolism in patients with lung cancer receiving chemotherapy: a combined analysis of PROTECHT and TOPIC-2 studies"  
Journal of Thrombosis and Haemostasis 2010; 8: 649-51

35) "Incidence and predictors of venous thromboembolism in post-acute care patients. A prospective cohort study"  
Thromb Haemost 2010 ; 104: 734-40

36) "The influence of physical activity performed at 20-40 years of age on cardiovascular outcome in medical patients aged 65-75"  
Italian Journal of Medicine 2011; 5: 114-9

37) "Clinical profile and predictors of in-hospital outcome in patients with heart failure: the FADOI "CONFINE" study"  
Int J Cardiol 2011; 152: 88-94

38) "Depressive symptoms and disability in acute patients with comorbidities in departments of internal medicine"  
Italian Journal of Medicine 2011; 5: 261-8

39) "Commentary to: Clinical profile and predictors of in-hospital outcome in patients with heart failure: the FADOI "CONFINE" study"  
Int J Cardiol 2012

40) "Real-world economic burden of venous thromboembolism and antithrombotic prophylaxis in medical inpatients"  
Thromb Res 2013; 131: 17-23

41) "Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry"  
Thromb Res 2013; 131: 24-30

42) "Current presentation and management of 7148 patients with atrial fibrillation in cardiology and internal medicine hospital centers: the ATA-AF study"  
Int J Cardiol 2013; 167: 2895-903

43) "Decision making for oral anticoagulant therapy in atrial fibrillation: results of the ATA-AF study"  
Eur J Inter Med 2013; 24: 324-32

44) "Effects of iloprost on pain-free walking distance and clinical outcome in patients with severe IIb stage peripheral arterial disease. The FADOI 2bPILOT study"  
Eur J Clin Invest 2013; 43: 1163-70

45) "Complexity in hospital Internal Medicine departments: what are we talking about?"  
Italian Journal of Medicine 2013; 7: 142-155

46) "E-learning to improve the drug prescribing in the hospitalized elderly patients: the ELICADHE Feasibility Pilot Study"  
Aging Clinical and Experimental Research 2014; 26: 435-43

47) "Influence of recent immobilization or surgery on mortality in cancer patients with venous thromboembolism"  
Thromb Res 2014; 133 Suppl.2: S29-34

48) "Effectiveness of an educational intervention on the management of type 2 diabetic patients hospitalized in Internal Medicine: results from the FADOI-DIAMOND study"  
Acta Diabetologica 2014; 51: 765-70

49) "Home versus in-hospital treatment of outpatients with acute deep venous thrombosis of the lower limbs"  
J Vasc Surg 2014; 59: 1362-7

50) "The effect of low molecular weight heparin in cancer patients: the mirror image of survival?"  
Blood 2014; 124: 155-6

51) "Sex differences in patients receiving anticoagulant therapy for venous thromboembolism"  
Medicine (Baltimore) 2014; 93: 309-17

52) "Pain management in Internal Medicine and effects of a standardized educational intervention the FADOI-DOMINO Study"  
Int J Clin Pract 2015; 69: 33-40

53) "High prevalence of fragility vertebral fractures in patients hospitalized in Internal Medicine Units. Result of the POINT (Prevalence of Osteoporosis in INTernal medicine) study."  
Bone 2015; 74: 114-20

54) "Infection as a cause of immobility and occurrence of venous thromboembolism: analysis of 1,635 medical cases from the RIETE registry"  
J Thromb Thrombolysis 2016; 41: 404-12

55) "Organizational impact of the introduction of a new portable syringe pump for iloprost therapy in Italian hospital settings"  
Current Drug Therapy 2015; 10: 105-12

56) "Rate and duration of hospitalization for deep vein thrombosis and pulmonary embolism in real world clinical practice"

Ann Med 2015; 47: 546-54

- 57) "Risk factors for hypoglycemia in patients with type 2 diabetes, hospitalized in Internal Medicine wards. Findings from the FADOI-DIAMOND study"  
Diabetes Research and Clinical Practice 2016; 115: 24-30
- 58) "Prulifloxacin vs levofloxacin for exacerbation of COPD after failure of other antibiotics"  
COPD 2016; 13: 555-60
- 59) "Sex-gender and atrial fibrillation treatment in the ATA-AF study"  
Italian Journal of Medicine 2016; 10: 207-12
- 60) "E-learning in order to improve drug prescription for hospitalized older patients: a cluster-randomized controlled study"  
British Journal of Clinical Pharmacology 2016; 82: 53-63
- 61) "Nutraceuticals approaches to homocysteine lowering in hypertensive subjects at low cardiovascular risk: a multicenter, randomized clinical trial"  
Journal of Biological Regulators and Homeostatic Agents 2016; 30: 921-7
- 62) "Epidemiology and outcome of Clostridium difficile infections in patients hospitalized in Internal Medicine. Findings from the nationwide FADOI-PRACTICE study"  
BMC Infectious Diseases 2016; 16: 656
- 63) "La Medicina e la Ricerca disease, patient and person-oriented"  
Quaderni Ital J Med 2017; 1: 27-32
- 64) "Italian Intersociety Consensus on DOAC use in Internal Medicine"  
Internal and Emergency Medicine 2017; 12: 387-406
- 65) "Misdiagnosis of vertebral fractures on local radiographic readings of the multicentre POINT (Prevalence of Osteoporosis in INTernal medicine) study"  
Bone 2017; 101: 230-235
- 66) "Misdiagnosis of vertebral fractures: unresolved but resolvable problem"  
Bone 2017; 105: 308
- 67) "Self-reported hypertension, dyslipidemia and hyperuricemia management by Italian Internal Medicine Units: a national survey of the FADOI Study Group on Cardiovascular Medicine"  
Italian Journal of Medicine 2017; 11: 371-378
- 68) "The complexity of patients hospitalized in Internal Medicine wards evaluated by FADOI-COMPLIMED score(s). A hypothetical approach"  
PLoS One 2018 Apr 16; 13(4): e0195805
- 69) "Apixaban versus Dalteparin for the treatment of acute venous thromboembolism in patients with cancer. The Caravaggio study"  
Thrombosis Haemost 2018; 118(9): 1668-1678
- 70) "Gender differences in pain prevalence, characteristics, assessment and treatment in Internal Medicine patients: a post-hoc analysis of the FADOI-DOMINO study"  
Italian Journal of Medicine 2018; 12: 213-218
- 71) "Factors associated with anticoagulation prescription in elderly patients with atrial fibrillation"  
European Journal of Preventive Cardiology 2019; 26: 660-663
- 72) "What quality and safety of care for patients admitted to clinically inappropriate wards: a systematic review"  
Journal of General Internal Medicine 2019; 34: 1314-1321
- 73) "Antithrombotic treatment of VTE in cancer: it may change"  
Journal of Blood and Lymph 2019 (in press)

74) "Prophylaxis of venous thromboembolism after hospital discharge in Internal Medicine: findings from the observational FADOI-NoTEVole study"  
Thromb Haemost 2019; 119: 2043-2052

75) "Rivaroxaban for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer. Design of the PRO-LAPS II study"  
European Journal of Internal Medicine 2020; 72: 53-59

76) "Acquired factor XIII deficiency inducing recurrent and fatal bleeding, description of a case"  
Journal of Blood Medicine 2020; 11: 43-45

77) "Derivation and validation of a prediction model for venous thromboembolism in primary care"  
Thrombosis and Haemostasis 2020; 120: 692-701

78) "Apixaban for the treatment of venous thromboembolism associated with cancer"  
New England Journal of Medicine 2020; 382: 1599-1607

79) "The increasing need for a new Italian legislation to facilitate execution of observational studies assuring ethics and the highest standards of scientific and methodological quality"  
Annali dell'Istituto Superiore di Sanità 2020; 56: 257-259

80) "Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio Study"  
Thrombosis and Haemostasis 2021; 121: 616-624

81) "Clinical characteristics, management and outcome of patients with invasive candidiasis hospitalized in Internal Medicine Units. Findings from a registry by the Italian Scientific Society FADOI"  
Infection 2021; 49: 277-285

82) "Lessons learned from CoViD-19 for clinical research operations in Italy: what have we learned and what can we apply beyond?"  
Tumori 2021; 107: 6-11

83) "Acute cardiovascular events in patients with community acquired pneumonia: results from the observational prospective FADOI-ICECAP Study"  
BMC Infectious Diseases 2021; 21: 116

84) "Not-for-profit observational study to evaluate the quality and safety of care in patients "outliers" hospitalized with medical diseases – Study Protocol of Safety Issues and Survival For Medical Outliers (SISIFO study)"  
Italian Journal of Medicine 2021; 15: 41-44

85) "Health outcomes in COPD smokers using heated tobacco products: a 3-year follow-up"  
Internal and Emergency Medicine 2021; 16: 687-696

86) "Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer"  
Thrombosis and Haemostasis 2022; 122: 796-807

87) "Optimization of RAASi therapy with new potassium binders for patients with heart failure and hyperkalemia: rapid review and meta-analysis"  
Journal of Clinical Medicine 2021; 10: 5483

88) "Prevalence, management and impact of chronic obstructive pulmonary disease in atrial fibrillation: a systematic review and meta-analysis of 4,200,000 patients"  
European Heart Journal 2021; 42: 3541-3554

89) "Recurrent venous thromboembolism and major bleeding in patients with localized, locally advanced or metastatic cancer: an analysis of the Caravaggio study"  
European Journal of Cancer 2022; 165: 136-145

90) "Digital therapeutics in oncology: findings, barriers and prospects. A narrative review"

Annals of Research in Oncology 2022; 2(1): 55-69

- 91) "Rivaroxaban versus placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer"  
Blood 2022; 140(8): 900-908
- 92) "Intentional Rounding versus Standard of Care for patients hospitalised in Internal Medicine wards: results from a cluster-randomised nation-based study"  
Journal of Clinical Medicine 2022; 11: 3976
- 93) "The use of risk scores for thromboprophylaxis in medically ill patients – Rationale and design of the RICO trial"  
Thrombosis and Haemostasis 2022 (in press)
- 94) "Decentralised Clinical Trials (DCTs): a few ethical considerations"  
Frontiers in Public Health 2022; 10: 1081150
- 95) "FADOI survey on chronic kidney disease and anaemia in Internal Medicine Departments in Italian Hospitals"  
Italian Journal of Medicine 2023 (in press)
- 96) "Understanding the potential of digital therapies in implementing the standard of care for depression in Europe"  
European Psychiatry 2023 (published online ahead of print) <https://doi.org/10.1192/j.eurpsy.2023.2453>
- 97) "Privacy and retrospective observational research: a guarantee, not an obstacle"  
Annals of Research in Oncology 2023; 3 (4): 142-146